{
  "moduleId": "ind",
  "title": "Investigational New Drug Application",
  "sections": [
    {
      "id": "intro",
      "title": "Introduction",
      "description": "Provides an overview of the IND application and the investigational product.",
      "regulatoryGuidance": [
        "Include a brief description of the drug, including its formulation and route of administration.",
        "Provide a high-level summary of the development program and its objectives.",
        "Reference relevant FDA regulations (21 CFR Part 312)."
      ]
    },
    {
      "id": "cmc",
      "title": "Chemistry, Manufacturing, and Controls",
      "description": "Describes the composition, manufacture, and specifications of the drug substance and drug product.",
      "regulatoryGuidance": [
        "Include information on drug substance (active ingredient) and drug product (final formulation).",
        "Describe manufacturing process, quality controls, and stability data.",
        "Address any novel excipients or delivery systems used in the formulation."
      ]
    },
    {
      "id": "pharmacology",
      "title": "Pharmacology and Toxicology",
      "description": "Summarizes the nonclinical studies performed to support the safety of the investigational product.",
      "regulatoryGuidance": [
        "Include summaries of pharmacology, ADME, and toxicology studies.",
        "Address safety pharmacology and toxicokinetics.",
        "Justify the proposed clinical dose based on nonclinical findings."
      ]
    },
    {
      "id": "clinical",
      "title": "Clinical Protocol",
      "description": "Provides detailed information about the proposed clinical investigation.",
      "regulatoryGuidance": [
        "Include study objectives, design, and endpoints.",
        "Describe subject population, inclusion/exclusion criteria, and safety monitoring.",
        "Address statistical analysis plan and stopping rules."
      ]
    }
  ]
}